RxDoctor Payments Data

Linda Davt

Primary Care · Hackensack, NJNPI 1760945299

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.8% of the total across 243 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 41 manufacturers reported payments, led by Novo Nordisk at 37.0% of the total. Among primary care clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,385in general payments, 2019–2025

Across 243 payments — averaging $22.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Intra-sana Laboratories$535
  • Pfizer$407
  • Exact Sciences$325
  • Lilly USA, LLC$261
  • Boston Scientific$213
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$5,373100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,385 in reported general payments places this provider in the 95th percentile of 330 primary care providers in New Jersey.

See all primary care providers in New Jersey

Medicare billing

Part B allowed, 2024
$9,661
Medicare patients
31
Services billed
153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$33,309
Atorvastatin Calcium36$800
Topiramate20$417
Omeprazole14$402
Levothyroxine Sodium26$321
Losartan Potassium17$281
Rosuvastatin Calcium12$255
Vitamin D2Ergocalciferol (Vitamin D2)12$251
Metoprolol Succinate11$176
Levocetirizine Dihydrochloride14$153
Hydrochlorothiazide13$129
Metoprolol Tartrate13$127
Simvastatin12$121
Amlodipine Besylate11$109
Metformin Hcl11$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,992$33,30921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 330 primary care providers in New Jersey.

Other primary care in Hackensack

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →